A novel locus for autosomal dominant non-syndromic hearing loss, DFNA31, maps to chromosome 6p21.3

R L Snoeckx, H Kremer, R J H Ensink, K Flothmann, A de Brouwer, R J H Smith, C W R J Cremers, G Van Camp

**Background:** Non-syndromic hearing loss is the most genetically heterogeneous trait known in humans. To date, 51 loci for autosomal dominant non-syndromic sensorineural hearing loss (NSSHL) have been identified by linkage analysis.

**Objective:** To investigate the genes involved in a Dutch family with NSSHL.

**Methods:** Linkage analysis in a large Dutch pedigree with progressive bilateral loss of the mid and high frequencies, in which a novel dominant locus for postlingual NSSHL (DFNA31) has been identified.

**Results:** DFNA31 was found to be located in a 7.5 cM region of chromosome 6p21.3 between D6S276 (telomeric) and D6S273 (centromeric), with a maximum two point LOD score of 5.99 for D6S1624. DNA sequencing of coding regions and exon/intron boundaries of two candidate genes (*POU5F1, GABBR1*) in this interval did not reveal disease causing mutations.

**Conclusions:** Haplotype analysis indicated that the genetic defect in this family does not overlap the DFNA13 and DFNA21 regions that are also located on 6p. Identification of the disease gene will be of major importance in understanding the pathophysiology of hearing impairment.

The most common sensory defect in humans is hearing loss. About one in 650 children suffers from hearing impairment before speech acquisition. This prelingual deafness has a genetic cause in 60% of the cases. In nearly all cases it is monogenic and has an autosomal recessive (75%), autosomal dominant (20–25%), or X linked (1–4%) inheritance pattern. More common is postlingual hearing loss, which affects 10% of the population by the age of 60 and 50% by the age of 80. In most cases the aetiopathology is multifactorial, resulting from a combination of genetic and environmental factors. This complex trait is called presbyacusis and is the commonest form of adult onset hearing loss. Monogenic forms of postlingual progressive hearing impairment are also seen. In these families, the onset is earlier than presbyacusis, and the inheritance is nearly always autosomal dominant. Lists of all currently known genes and loci for non-syndromic hereditary hearing impairment can be obtained from the hereditary hearing loss homepage (http://www.uia.ua.ac.be/dnalab/hhh). Identification of genes for hereditary hearing impairment is an important step towards clarifying the biology of hearing and deafness at a molecular level.

**METHODS**

**Nomenclature**

Gene symbols used in this article follow the recommendations of the HUGO gene nomenclature committee.

**Family data**

In this study we investigated a four generation Dutch family with autosomal dominant sensorineural hearing impairment. Informed consent was obtained from all study participants and from the parents of minors. A clinical history interview of members of this family was undertaken by one of the investigators, with special emphasis on identifying potential environmental causes of hearing loss or on evidence of syndromic forms of deafness. Otoscopic examination was done, along with pure tone audiometry for air conduction (125–8000 Hz) and bone conduction (250–4000 Hz).

Blood samples were collected from 39 pedigree members. DNA was extracted from leucocytes according to standard methods. Of the study subjects from whom DNA samples were obtained, 12 had hearing impairment, 15 were unaffected, and 12 had an unclear diagnosis or were too young to have symptoms of hearing impairment (fig 1).

**Clinical features**

Clinical investigations of this family have been reported by Ensink et al. Briefly, hearing impairment in the family is, apart from presbyacusis, most pronounced at 1 to 2 kHz. On the basis of audiograms and clinical investigations, 12 individuals were classified as affected and included in the linkage analysis. The estimated age of onset varied between frequencies, ranging from five years in the low frequencies to 12 years in the high frequencies. Fifteen persons above the age of 12 were classified as unaffected. In the remaining 12 persons, the clinical diagnosis was unclear because of an atypical audiometric pattern or because the age of onset was not yet reached. These subjects were not included in LOD score calculations and are not represented in fig 1.

**Genotyping and linkage analysis**

Twenty microsatellite markers were used to analyse the first 13 DFNA loci. Markers for the refinement of the critical interval were taken from the Généthon human linkage map. The order of these markers was established on the basis of the NCBI physical map (http://www.ncbi.nlm.nih.gov). All the genotyping was done by polymerase chain reaction (PCR) and polyacrylamide gel electrophoresis, using standard procedures. Two point linkage analysis was conducted for each marker using the MLINK program from the LINKAGE package, version 5.1. Two point LOD scores between the deafness locus and each marker were calculated under a fully penetrant autosomal dominant mode of inheritance, setting the disease allele frequency to 0.00001 and considering marker allele frequencies as being equal to each other. We used the observed numbers of alleles in the pedigree (N) in the LOD score calculations and set the allele frequencies at 1/N.

**Candidate gene analysis**

Primers were designed for the amplification of coding regions and exon–intron boundaries of *POU5F1* (MIM 164177) and...
RESULTS
Microsatellite markers for known DFNA loci were analysed in numerical order. DFNA1 to DFNA12 were excluded by means of linkage analysis. Markers linked to DFNA13 showed positive LOD scores, suggesting linkage. Additional STRP markers in this chromosomal region were analysed, confirming linkage with maximum two point LOD scores up to 5.99 (table 1), and delineating a candidate region between markers D6S276 and D6S273. At the time of analysis, the most comprehensive genetic map of the human genome was the Genéthon human linkage map. On this map, the key recombinant markers—D6S276 and D6S273—were located, respectively, at position 44.9 cM and 45.4 cM of chromosome 6p, suggesting that the candidate region was very small (0.5 cM). The telomeric key recombinant marker of the DFNA13 region, D6S1666, had the same genetic position as D6S273 (45.4 cM). For this reason we concluded that the family was linked to DFNA13, and most probably had a mutation in the COL11A2 gene, responsible for hearing impairment in several families linked to the DFNA13 region.

DISCUSSION
We analysed the complete coding region of the COL11A2 gene but did not find a disease causing mutation, which was puzzling. Subsequently, tremendous progress was made in the accuracy of available genetic and physical maps, as a result of the human genome project. These newly developed physical maps revealed serious errors in the Genéthon map of chromosome 6p21.3. It became clear that the current family was linked to a region non-overlapping and telomeric of the DFNA13 locus, and a new locus name (DFNA31) was obtained from the HUGO nomenclature committee. A physical map of the 6p21.3 region based on recent data from the National Center for Biotechnology Information and containing all relevant genetic markers is given in fig 2. The new map shows that the candidate region for the current family does not include the COL11A2 gene, explaining why no disease causing mutation was found in the COL11A2 gene.

Because of the large physical distance between COL11A2 and DFNA31, a positional effect of the COL11A2 gene is highly unlikely, and COL11A2 can be excluded as the gene for DFNA31. In addition, the size of the candidate region, flanked by D6S276 and D6S273, was larger than previously anticipated on the basis of the Genéthon genetic map, and spans 7.5 million base pairs (fig 2).

A third locus for non-syndromic hearing impairment, DFNA21, has been localised to chromosome 6p. DFNA21 is flanked by the marker D6S1691 at the centromeric site (de Brouwer A et al, unpublished data), and as a result does not overlap DFNA13 or DFNA31. The localisation of different genes for non-syndromic hearing impairment in close proximity is not surprising. Non-syndromic hearing impairment is the most genetically heterogeneous disease known. Currently, there are close to 100 different localisations, and new genes are localised at a rapid pace (for an overview, see the hereditary hearing loss homepage, http://www.uia.ua.ac.be/dnalab/hhh). It can be expected that, just by chance, some of these genes will be localised closely together.
Another example is the DFNA2 locus, for which three different genes have been implicated.

The 7.5 cM DFNA31 interval includes most of the histone gene cluster and a part of the MHC region. Within the entire MHC region, more than 200 genes have so far been identified, making it one of the most gene dense and complex regions of the genome. Because HLA genes have their function in immunological processes, a specific pathophysiological function in hearing impairment is not very likely. Many of the other genes in our region are ones that encode for histones. They are not considered good candidate genes for hearing impairment because of their elementary function. We did find two genes in the DFNA31 region that are very interesting as possible candidates. The first of these, GABBR1, encodes for the β receptor of the neurotransmitter GABA, which is an important neurotransmitter in the sound perception system and was therefore a good candidate gene which is an important neurotransmitter in the sound perception system and was therefore a good candidate gene for hearing impairment—POU5F1, encoding for the POU domain. Two POU genes have already been reported to cause hearing impairment—POU5F1 and POU4F3; these are responsible for DFN3 and DFNA15, respectively. However, DNA sequencing of coding regions and exon-intron boundaries of the two genes did not reveal a disease causing mutation.

The ultimate cloning of the gene causing DFNA31 will provide further insights into our understanding of the molecular pathophysiology of late onset hearing loss.

ACKNOWLEDGEMENTS

We are grateful to all family members for their collaboration in this study. The study was supported by grants from the University of Antwerp and from the Vlaams Fonds voor Wetenschappelijk Onderzoek (FWO) to GVC. RLS holds a predoctoral research position with the Instituut voor de aanmoediging van Innovatie voor Wetenschap en Technologie in Vlaanderen (IWT-Vlaanderen). This research was undertaken in the framework of the Interuniversity Attraction Poles programme PS19 of the Federal Office for Scientific, Technical, and Cultural Affairs, Belgium.

Authors’ affiliations

R L Snoeckx, K Flothmann, G Van Camp, Department of Medical Genetics, University of Antwerp, Belgium

H Kremer, R J H Ensink, A de Brouwer, C W R J Cremer, Departments of Otorhinolaryngology and Head and Neck Surgery, University of Nijmegen, Netherlands

R J H Smith, Department of Otolaryngology, University of Iowa Hospitals and Clinics, Iowa City, USA

Correspondence to: Professor G Van Camp, Department of Medical Genetics, University of Antwerp, Universiteitsplein 1, Antwerp 2610, Belgium; gvcamp@ua.ua.ac.be

Revised version received 8 August 2003

Accepted 14 August 2003

REFERENCES


11 McGuirt WT, Prasad SD, Griffith AJ, Kunst HP, Green GE. Mutations in COL1A2 cause non-syndromic hearing loss (DFNA13). Nat Genet 1999;23:413–19


15 Milner CM, Campbell RD. Genetic organization of the human MHC class III region. Front Biosci 2001;6:194–26


17 Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today 1993;14:349–52


A novel locus for autosomal dominant non-syndromic hearing loss, DFNA31, maps to chromosome 6p21.3

R L Snoeckx, H Kremer, R J H Ensink, K Flothmann, A de Brouwer, R J H Smith, C W R J Cremers and G Van Camp

J Med Genet 2004 41: 11-13
doi: 10.1136/jmg.2003.010702

Updated information and services can be found at:
http://jmg.bmj.com/content/41/1/11

These include:

References
This article cites 17 articles, 2 of which you can access for free at:
http://jmg.bmj.com/content/41/1/11#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Genetic screening / counselling (886)
Molecular genetics (1254)
Clinical genetics (256)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/